Stock Quote – ISR (NYSE)

Search for:

Brachytherapy in the News:

New treatments mean better prostate cancer survival rates November 4, 2016
Intermediate-Risk Prostate Cancer May be Well-Controlled with Brachytherapy Alone October 25, 2016
In favorable intermediate-risk prostate cancer, brachytherapy alone suffices October 7, 2016

Investors

Events and Presentations
Stock Quote – ISR (NYSE)
Press Releases
Audit Committee
Compensation Committee Charter
Nominations and Corporate Governance Committee
Code of Ethics for Senior Leadership
Code of Conduct and Ethics

Patients
Clinicians
Cesium Pioneers
Why Brachytherapy?
Why Cesium-131?

About
Contact
News
Careers
Investors

About

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Disclosure

The physicians featured on this website may have prior or current relationships with IsoRay. These relationships may include, for example: membership on IsoRay’s Advisory Board; participation as a clinical investigator in research conducted on IsoRay products; provision of consultation or training services; or engagement as a prospective partner in the development of new products. Many of these physicians have received or continue to receive compensation from IsoRay in one form or another. The principal nature of a specific physician’s relationship is disclosed on this website adjacent to language featuring that physician.

Home
About
Contact
Terms of Use

Facebook
Twitter
RSS

Stock Quote – ISR (NYSE)

Categories

Brachytherapy in the News:

Investors